0
0
NEW DELHI — In a development that exposes critical vulnerabilities in India’s pharmaceutical supply chain, the Delhi High Court has stepped in to investigate the alleged illegal diversion and export of high-value, life-saving medicines. On May 19, 2026, a Division Bench comprising Chief Justice Devendra Kumar Upadhyaya and Justice Tejas Karia issued a formal notice to the Union government and multiple regulatory authorities. The court is seeking immediate answers regarding a parallel market where critical oncology therapies, imported and legally designated “for sale in India only,” are reportedly being smuggled out of the country for higher foreign profits.
The judicial intervention stems from a Public Interest Litigation (PIL) filed by petitioners Ripan Wadhwa and Ramesh Kumar Sharma. The petition outlines a sophisticated scheme where merchant exporters allegedly procure high-value medicines from the domestic market and intermingle them with legitimate export consignments. This practice directly threatens the fragile safety net of domestic drug availability, leaving Indian patients—particularly those battling advanced cancers—vulnerable to severe treatment disruptions and artificial shortages.
The Crisis of Access: Cancer Care Out of Reach
The timing of the High Court’s scrutiny aligns with growing concerns over the affordability of advanced cancer treatments in India. For many families, oncology medications represent the difference between life and death, yet their costs remain astronomically prohibitive.
To put the financial strain into context, a landmark study published by the Tata Memorial Centre (TMC) and ACTREC in the journal Head & Neck highlighted the severe economic barriers associated with immunotherapy, a type of treatment that stimulates the patient’s own immune system to fight cancer cells:
| Immunotherapy Drug | Financial Impact on Average Indian Family |
| Pembrolizumab (Keytruda) | Six months of treatment costs nearly 80 times the average monthly income. |
| Nivolumab (Opdivo) | Six months of treatment exceeds 20 times the average monthly income. |
The TMC-ACTREC study concluded that fewer than 2% of Indian patients who are medically eligible for pembrolizumab can actually afford to access it. Researchers noted that the financial trade-offs are staggering: the funds required to treat a single patient with pembrolizumab could alternatively fund lower-cost targeted therapies for 18 to 22 patients.
When these scarce, price-controlled, or domestically allocated drugs are illicitly siphoned out of the local market, the consequences extend beyond corporate non-compliance—it directly impacts the right to healthcare for economically vulnerable citizens.
Unmasking the Systemic Gaps
According to Advocate Dhruv Chawla, representing the petitioners, the pharmaceutical supply chain suffers from systemic oversight failures that allow merchant exporters to exploit loopholes. The PIL details several distinct structural vulnerabilities:
-
Fragmented Oversight: A profound lack of real-time data sharing and coordination between domestic drug regulatory authorities and customs border control.
-
Weak Export Verification: Inadequate physical and documentary verification mechanisms at ports of exit, allowing domestic stock to be intermingled with authorized export cargo.
-
Paper-Only Wholesaling: The exploitation of merchant exporter licenses, where businesses purchase price-controlled medicines from local distributors and reroute them abroad without proper regulatory authorization.
[Domestic Manufacturer/Importer]
│
▼ (Labeled "For Sale in India Only")
[Domestic Wholesaler]
│
├──► SHOULD GO TO: Indian Hospitals & Patients (Price Controlled)
│
└──► ALLEGED DIVERSION: Merchant Exporter (Intermingled Consignments) ──► Illegal Foreign Export
This regulatory blind spot is not entirely new to enforcement agencies. The PIL relies heavily on an Office Memorandum issued by the Central Drugs Standard Control Organisation (CDSCO) which explicitly acknowledged that pharmaceutical products marked “for sale in India only” were being illicitly exported. The CDSCO directed an immediate halt to the practice at the time, but the petitioners argue that no comprehensive forensic audit or criminal investigation followed.
In response, the Delhi High Court has ordered the CDSCO to submit a detailed counter-affidavit specifically outlining what concrete enforcement steps have been taken to police this circular.
A Precedent of Parallel Markets
While the diversion of multi-lakh-rupee oncology drugs represents a high-stakes financial crime, the mechanics mirror previous supply chain breakdowns in India. Public health experts point to a massive pharmaceutical racket exposed in Uttar Pradesh, where an illegal ₹704-crore parallel supply chain diverted codeine-based cough syrups into non-therapeutic channels.
Though that case involved domestic substance abuse rather than international smuggling, the underlying vulnerability was identical: a web of shell wholesalers existing entirely on paper acting as “billing points” to mask the movement of medicines away from legitimate retail pharmacies.
“The structural issue across these cases is traceability,” explains a public health policy analyst not involved in the litigation. “Whether a drug is diverted for illicit local abuse or smuggled out for international arbitrage, it represents a failure to secure the supply chain from the point of manufacture to the point of patient delivery. When high-value cancer drugs disappear into these shadow channels, it creates an artificial scarcity that drives domestic prices up even further.”
Balancing Public Health and Export Interests
The High Court’s aggressive stance has introduced palpable tension within the pharmaceutical sector. Organizations like the Pharma Manufacturers Exporters (FPME) have previously voiced severe concerns regarding sweeping export bans on drugs carrying domestic labels, arguing that over-regulation could inadvertently penalize legitimate trade and weaken India’s standing as the “pharmacy of the world.”
However, the government maintains that strict domestic labeling is a protective public health mechanism. The policy is designed to ensure equitable access and stable pricing for Indian citizens, shielding the domestic market from supply shocks caused by external economic incentives.
The allegations raised in the PIL remain unproven, and the Delhi High Court has made no final determination on the merits of the case. Regulatory critics caution that the scale of the diversion remains unknown until an independent agency conducts a thorough investigation. Furthermore, there is a risk that overly broad enforcement could disrupt legitimate pharmaceutical logistics or misidentify authorized cross-border shipments as illegal smuggling.
The Union government, CDSCO, and associated revenue intelligence agencies have been granted time to file their formal responses before the next scheduled court hearing on August 19, 2026. The upcoming filings will offer the public a clearer picture of how the state intends to bridge the regulatory gaps between trade and healthcare, preserving vital medical access for its citizens.
References
- https://tennews.in/delhi-hc-seeks-centres-response-on-diversion-of-life-saving-drugs/
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
